Ryujiro Suzuki, Masashi Yamamoto, Hideo Saka, Hiroyuki Taniguchi, Joe Shindoh, Yoshimasa Tanikawa, Fumio Nomura, Hideo Gonda, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Kaoru Shimokata
BACKGROUND: Cyclooxygenase (COX-2) overexpression is seen in many malignancies including lung cancer. Recent pre-clinical studies have shown that selective COX-2 inhibitors have demonstrated promising results when used with chemotherapy. Based on these observations, we assessed the efficacy and tolerability of the combination chemotherapy consisting of carboplatin and paclitaxel with meloxicam, a selective COX-2 inhibitor. METHODS: Forty-four patients with stage IIIB or IV non-small cell lung cancer (NSCLC), Eastern Cooperative Oncology Group performance status (PS) 0 or 1, who had adequate organ function, were eligible...
January 2009: Lung Cancer: Journal of the International Association for the Study of Lung Cancer